VSIG4 and myasthenia gravis: In conclusion, our results demonstrated that the targeted complement inhibitor CRIg/FH may hold great potential for MG treatment, in which the therapeutic effect results not only from the direct complement inhibition but also from the modulation of adaptive immune responses.